theranexus Archives - IRIS CAPITAL INVESTMENT

17 Dec 24

THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE AN AGREEMENT LICENSE FOR THE MARKETING OF THERANEXUS TX01 IN THE TREATMENT OF TWO RARE NEUROLOGICAL DISEASES

Lyon, France, dec 17, 2024 – Theranexus, an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, and Exeltis, a global pharmaceutical company of the Insud Pharma group, announce the signing of a licensing and distribution agreement for the commercialization of Theranexus’ TX01, a new formulation of a…

20 Nov 23

TheraVet announces the setting up of an equity-linked financing facility and updates on its financing strategy

Gosselies, Belgium, Nov 20, 2023 – TheraVet announces the setting up of an equity-linked financing facility and updates on its financing strategy DOWNLOAD THERAVET press release

13 Jul 23

THERANEXUS raises around 3.1 million euros in fundraising

Lyon, Jul 13, 2023 – THERANEXUS raises around 3.1 million euros in fundraising DOWNLOAD THERANEXUS press release

21 Jan 22

THERANEXUS Publishes its cash position as of 31 december 2021

Lyon, Jan 13, 2022 – THERANEXUS publishes its cash position as of 31 december 2021. Implementation of a new equity line. DOWNLOAD THERANEXUS press release

19 Jan 21

Theranexus implements a new equity line of an amount of up to €8.4 million in total over 12 months

Lyon, 18 January 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurologicaldiseases and pioneer in the development of drug candidates modulating the interaction between neurons and glialcells, presents an update on its activities and announces the strengthening of its financial visibilityfor the medium term.

09 Jul 20

Theranexus implements a Mandatory Convertible Bond facility

THERANEXUS ANNOUNCES ITS CASH POSITION AS OF 30 JUNE 2020 ANDIMPLEMENTATION OF A MANDATORY CONVERTIBLE BOND FACILITY • Pro forma cash of €13.3 M at 30 June 2020• Implementation of financing for a maximum total of €4.2 million over 12 months through the issuance of warrants to subscribe mandatory convertible…

theranexus

THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE AN AGREEMENT LICENSE FOR THE MARKETING OF THERANEXUS TX01 IN THE TREATMENT OF TWO RARE NEUROLOGICAL DISEASES

TheraVet announces the setting up of an equity-linked financing facility and updates on its financing strategy

THERANEXUS raises around 3.1 million euros in fundraising

THERANEXUS Publishes its cash position as of 31 december 2021

Theranexus implements a new equity line of an amount of up to €8.4 million in total over 12 months

Theranexus implements a Mandatory Convertible Bond facility

Links